keyword
https://read.qxmd.com/read/38437773/effectiveness-and-safety-of-different-catechol-o-methyl-transferase-inhibitors-for-patients-with-parkinson-s-disease-systematic-review-and-network-meta-analysis
#1
REVIEW
Wenshuo Wu, Xiaohui Lu, Liping Zhang, Du Hong
BACKGROUND: Levodopa treatment requires the addition of other drugs, such as catechol-O-methyl transferase (COMT) inhibitors, to alleviate motor fluctuations in advanced parkinson's disease (PD). However, the optimal strategy, including the type and dose of COMT inhibitors remains unknown. This systematic review and network meta-analysis aimed to assess the efficacy and safety of different COMT inhibitors and for treating PD patients. METHODS: PubMed, Embase, Cochrane Library and Web of Science were screened up to November 20, 2022...
February 23, 2024: Clinical Neurology and Neurosurgery
https://read.qxmd.com/read/38287715/decreased-hepatic-enzymes-reflect-the-decreased-vitamin-b6-levels-in-parkinson-s-disease-patients
#2
JOURNAL ARTICLE
Kensuke Ikenaka, Yuta Kajiyama, César Aguirre, Chi-Jing Choong, Seira Taniguchi, Junko Doi, Nan Wang, Takahiro Ajiki, Kotaro Ogawa, Keita Kakuda, Yasuyoshi Kimura, Hideki Mochizuki
The study aims to investigate the vitamin B6 levels in Parkinson's disease (PD) patients and their association with liver enzymes and evaluate how much dysregulation is associated with levodopa dose. Furthermore, to evaluate the effect of Opicapone, a catechol-o-methyl-transferase inhibitor, on vitamin B6 levels by monitoring the AST and ALT levels in patients treated with Levodopa-Carbidopa Intestinal Gel Infusion (LCIG). For these aims, serum vitamin B6 levels were measured (PD, n = 72 and controls, n = 31)...
February 2024: Pharmacology Research & Perspectives
https://read.qxmd.com/read/38244800/drug-induced-depressive-symptoms-an-update-through-the-who-pharmacovigilance-database
#3
JOURNAL ARTICLE
Julien Li, Yoann Zelmat, Wilhelm Storck, Edouard-Jules Laforgue, Antoine Yrondi, Alexander Balcerac, Agnès Sommet, François Montastruc
BACKGROUND: Depression is a highly incident condition and some drugs have been described as inducing or worsening depression. However, literature on this topic is rare and possibly outdated. METHODS: We performed disproportionality analyses using VigiBase®, the largest pharmacovigilance database worldwide to identify drugs associated with depression. Then we excluded drugs already known as depressogenic according to American Summary of Product Characteristics (SPC)...
January 18, 2024: Journal of Affective Disorders
https://read.qxmd.com/read/38153679/correction-to-objective-assessment-of-the-effects-of-opicapone-in-parkinson-s-disease-through-kinematic-analysis
#4
Matteo Bologna, Andrea Guerra, Donato Colella, Daniele Birreci, Davide Costa, Antonio Cannavacciuolo, Luca Angelini, Giulia Paparella, Angelo Antonini, Alfredo Berardelli, Giovanni Fabbrini
No abstract text is available yet for this article.
December 28, 2023: Neurological Sciences
https://read.qxmd.com/read/38091213/objective-assessment-of-the-effects-of-opicapone-in-parkinson-s-disease-through-kinematic-analysis
#5
JOURNAL ARTICLE
Matteo Bologna, Andrea Guerra, Donato Colella, Daniele Birreci, Davide Costa, Antonio Cannavacciuolo, Luca Angelini, Giulia Paparella, Angelo Antonini, Alfredo Berardelli, Giovanni Fabbrini
BACKGROUND: Opicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF time and end-of-dose motor fluctuations in Parkinson's disease (PD) patients. OBJECTIVES: In this study, we objectively assessed the effects of adding OPC to L-DOPA on bradykinesia in PD through kinematic analysis of finger movements. METHODS: We enrolled 20 treated patients with PD and motor fluctuations...
December 13, 2023: Neurological Sciences
https://read.qxmd.com/read/38058599/management-of-off-condition-in-parkinson-disease
#6
JOURNAL ARTICLE
Jessa Koch
Parkinson disease (PD) impacts nearly 1 million individuals in the United States. Nearly every patient with PD will require therapy with dopamine in the form of levodopa as the disease progresses. In more advanced stages of the disease, patients will experience motor fluctuations and require adjustment to their medication regimens to maintain good control of their symptoms. During the last 10 years, several new therapeutic treatment options have come to the market to treat motor fluctuations and improve patient quality of life...
December 2023: Mental Health Clinician
https://read.qxmd.com/read/38053568/opicapone-for-parkinson-s-disease
#7
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 2023: Australian Prescriber
https://read.qxmd.com/read/37798410/a-12-month-prospective-real-life-study-of-opicapone-efficacy-and-tolerability-in-emirati-and-non-white-subjects-with-parkinson-s-disease-based-in-united-arab-emirates
#8
JOURNAL ARTICLE
Vinod Metta, Huzaifa Ibrahim, Neha Muralidharan, Kislyn Rodriguez, Therese Masagnay, Judith Mohan, Arlet Lacsina, Abdullah Ahmed, Hani T S Benamer, Guy Chung-Faye, Rukmini Mrudula, Cristian Falup-Pecurariu, Carmen Rodriguez-Blazquez, Rupam Borgohain, Vinay Goyal, Kalyan Bhattacharya, K Ray Chaudhuri
Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients...
October 5, 2023: Journal of Neural Transmission
https://read.qxmd.com/read/37782207/the-role-of-opicapone-in-the-management-of-parkinson-s-disease-an-italian-consensus-through-a-combined-nominal-group-technique-and-delphi-approach
#9
JOURNAL ARTICLE
A Antonini, P Barone, P Calabresi, L Lopiano, F Morgante, F E Pontieri, M Sensi, F Stocchi
OBJECTIVE: Opicapone (OPC) is a third-generation peripheral catechol-O-methyl transferase inhibitor (COMT-i) approved as add-on therapy to levodopa/DOPA decarboxylase inhibitors (DDCI) combinations in Parkinson's disease (PD) patients with end-of-dose motor fluctuations. While the OPC effectiveness on motor symptoms is well known, there is still uncertainty about the timing of introduction, the management of levodopa dose, and the efficacy on non-motor symptoms (NMS). SUBJECTS AND METHODS: A group of PD experts participated in a consensus activity composed of the Nominal Group Technique (NGT) and the Delphi method to better define the role of OPC...
September 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/37724313/patients-preferences-for-adjunctive-parkinson-s-disease-treatments-a-discrete-choice-experiment
#10
JOURNAL ARTICLE
Michael Serbin, Connie Marras, Carol Mansfield, Colton Leach, Charles Yonan, Margaret Sheehan, Anne Donnelly, Olga Klepitskaya
BACKGROUND: Several adjunctive medications are available to reduce OFF time between levodopa/carbidopa (LD/CD) doses for people with Parkinson's disease (PD). OBJECTIVE: To explore how individuals with PD balance benefits and burdens when considering adjunctive medications. METHODS: US adults (30-83 years) with self-reported PD, currently treated with LD/CD, who experienced OFF episodes were recruited through the Fox Insight study to complete a discrete-choice experiment survey...
2023: Patient Preference and Adherence
https://read.qxmd.com/read/37489574/opicapone-versus-entacapone-head-to-head-retrospective-data-based-comparison-of-healthcare-resource-utilization-in-people-with-parkinson-s-disease-new-to-catechol-o-methyltransferase-comt-inhibitor-treatment
#11
COMPARATIVE STUDY
Glynn Harrison-Jones, Xiaocong Li Marston, Francesca Morgante, K Ray Chaudhuri, Guillermo Castilla-Fernández, Valentina Di Foggia
BACKGROUND AND PURPOSE: Motor fluctuations are a significant driver of healthcare resource utilization (HCRU) in people with Parkinson's disease (pwPD). A common management strategy is to include catechol-O-methyltransferase (COMT) inhibition with either opicapone or entacapone in the levodopa regimen. However, to date, there has been a lack of head-to-head data comparing the two COMT inhibitors in real-world settings. The aim of this study was to evaluate changes in HCRU and effect on sleep medications when opicapone was initiated as first COMT inhibitor versus entacapone...
October 2023: European Journal of Neurology
https://read.qxmd.com/read/37436881/structural-and-computational-analyses-of-the-unique-interactions-of-opicapone-in-the-binding-pocket-of-catechol-o-methyltransferase-a-crystallographic-study-and-fragment-molecular-orbital-analyses
#12
JOURNAL ARTICLE
Katsuki Takebe, Mamoru Suzuki, Takao Kuwada-Kusunose, Satoko Shirai, Kaori Fukuzawa, Tomoko Takamiya, Narikazu Uzawa, Hiroshi Iijima
A third-generation inhibitor of catechol O -methyltransferase (COMT), opicapone ( 1 ), has the 3-nitrocatechol scaffold as do the second-generation inhibitors such as entacapone ( 2 ) and tolcapone ( 3 ), but only 1 can sustainably inhibit COMT activity making it suitable for a once-daily regimen. These improvements should be attributed to the optimized sidechain moiety (oxidopyridyloxadiazolyl group) of 1 substituted at the 5-position of the 3-nitrocatechol ring. We analyzed the role of the sidechain moiety by solving the crystal structures of COMT/ S -adenosylmethionine (SAM)/Mg/ 1 and COMT/ S -adenosylhomocysteine (SAH)/Mg/ 1 complexes...
July 12, 2023: Journal of Chemical Information and Modeling
https://read.qxmd.com/read/37036498/the-real-life-effect-of-catechol-o-methyltransferase-inhibition-on-non-motor-symptoms-in-levodopa-treated-parkinson-s-disease-opicapone-versus-entacapone
#13
JOURNAL ARTICLE
Valentina Leta, Daniel J van Wamelen, Federico Aureli, Vinod Metta, Dhaval Trivedi, Pietro Cortelli, Carmen Rodriguez-Blazquez, Alexandra Rizos, K Ray Chaudhuri
OBJECTIVE: To evaluate the long-term, real-life effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson's disease (PwP). METHODS: A retrospective data analysis, with pre- and post-opicapone initiation data of 17 PwP with motor fluctuations compared to a comparable group of 18 PwP introduced on entacapone. The primary outcome was changes in the NMS Scale (NMSS) total score after 1-year follow-up. Secondary outcomes included changes in the NMSS domains, and Parkinson's Disease Sleep Scale (PDSS) total and item scores after the same time span...
July 2023: Journal of Neural Transmission
https://read.qxmd.com/read/36964457/clinical-benefit-of-mao-b-and-comt-inhibition-in-parkinson-s-disease-practical-considerations
#14
REVIEW
Martin Regensburger, Chi Wang Ip, Zacharias Kohl, Christoph Schrader, Peter P Urban, Jan Kassubek, Wolfgang H Jost
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson's disease patients. While selegiline/rasagiline and tolcapone/entacapone have been available on the market for more than one decade, safinamide and opicapone have been approved in 2015 and 2016, respectively. Meanwhile, comprehensive data from several post-authorization studies have described the use and specific characteristics of the individual substances in clinical practice under real-life conditions...
June 2023: Journal of Neural Transmission
https://read.qxmd.com/read/36688497/opicapone-pharmacokinetics-and-effects-on-catechol-o-methyltransferase-activity-and-levodopa-pharmacokinetics-in-patients-with-parkinson-disease-receiving-carbidopa-levodopa
#15
JOURNAL ARTICLE
Peter LeWitt, Grace S Liang, C Warren Olanow, Karl D Kieburtz, Roland Jimenez, Kurt Olson, Olga Klepitskaya, Gordon Loewen
OBJECTIVES: Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD). Catechol-O-methyltransferase inhibition can improve treatment outcomes by decreasing variability in circulating LD concentrations. Opicapone is a once-daily COMT inhibitor approved in the US adjunctive to carbidopa (CD)/LD in patients with Parkinson disease experiencing "OFF" episodes. This study aimed to evaluate the pharmacokinetics and pharmacodynamics of once-daily opicapone 50 mg adjunctive to CD/LD in patients with stable Parkinson disease...
January 23, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/36633762/off-time-treatment-options-for-parkinson-s-disease
#16
REVIEW
Margherita Fabbri, Raquel Barbosa, Olivier Rascol
Motor fluctuations (MF) are deemed by patients with Parkinson's disease (PD) as the most troublesome disease feature resulting from the increasing impairment in responsiveness to dopaminergic drug treatments. MF are characterized by the loss of a stable response to levodopa over the nychthemeron with the reappearance of motor (and non-motor) parkinsonian clinical signs at various moments during the day and night. They normally appear after a few years of levodopa treatment and with a variable, though overall increasing severity, over the disease course...
April 2023: Neurology and Therapy
https://read.qxmd.com/read/36508804/developmental-and-behavioral-toxicity-assessment-of-opicapone-in-zebrafish-embryos
#17
JOURNAL ARTICLE
Zhengkang Su, Kaiyu Guan, Yunbin Liu, Hai Zhang, Zhengwei Huang, Miaomiao Zheng, Ya Zhu, He Zhang, Weihong Song, Xi Li
The use of clinical psychoactive drugs often poses unpredictable threats to fetal development. Catechol-O-methyltransferase (COMT) is a key enzyme that regulates dopamine metabolism and a promising target for modulation of cognitive functions. Opicapone, a newly effective third-generation peripheral COMT inhibitor, is used for the treatment of Parkinson's disease (PD) and possibly to improve other dopamine-related disorders such as alcohol use disorder (AUD) and obsessive-compulsive disorder (OCD). The widespread use of opicapone will inevitably lead to biological exposure and damage to the human body, such as affecting fetal development...
December 9, 2022: Ecotoxicology and Environmental Safety
https://read.qxmd.com/read/36506576/adverse-event-profiles-of-adjuvant-treatment-with-opicapone-in-parkinson-s-disease-a-systematic-review-and-meta-analysis
#18
Luwen Xie, Xiaoyi Qi, Xuan Wang, Bing He, Yu Wang, Wei Zhang, Zehui Yu, Mingming Deng, Sicheng Liang, Muhan Lü
Background: Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor, has demonstrated efficacy in Parkinson's Disease (PD) patients with end-of-dose motor fluctuations. Objective: This study aimed to compare the short-term (<6 months) and long-term (≥6 months) tolerability of opicapone adjuvant treatment in PD patients. Method: Electronic databases including PubMed, Embase, Web of Science and Cochrane library were searched for randomized controlled trials (RCTs) and observational studies...
2022: Frontiers in Pharmacology
https://read.qxmd.com/read/36081875/the-safety-tolerability-of-opicapone-when-used-early-in-parkinson-s-disease-patients-with-levodopa-induced-motor-fluctuations-a-post-hoc-analysis-of-bipark-i-and-ii
#19
JOURNAL ARTICLE
José-Francisco Rocha, Georg Ebersbach, Andrew Lees, Eduardo Tolosa, Joaquim J Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Diogo Magalhães, Helena Gama, Patrício Soares-da-Silva
Introduction: Post-hoc analyses of the BIPARK-I and II trials previously demonstrated that opicapone (OPC) 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations, with enhanced efficacy in patients who were earlier vs. later in their disease course and levodopa treatment pathway. Complementary post-hoc analyses were performed to evaluate the safety/tolerability of OPC following the same pre-defined segmentation of the wide spectrum of duration of both PD and levodopa therapy, as well as of motor fluctuation history, in this patient population...
2022: Frontiers in Neurology
https://read.qxmd.com/read/36054562/effect-of-opicapone-on-levodopa-pharmacokinetics-in-patients-with-fluctuating-parkinson-s-disease
#20
RANDOMIZED CONTROLLED TRIAL
Joaquim J Ferreira, Werner Poewe, Olivier Rascol, Fabrizio Stocchi, Angelo Antonini, Joana Moreira, Bruno Guimarães, José-Francisco Rocha, Patrício Soares-da-Silva
BACKGROUND: Inhibiting catechol-O-methyltransferase extends the plasma half-life of levodopa, potentially allowing physicians to optimize the levodopa regimen in patients with Parkinson's disease (PD) experiencing motor fluctuations. OBJECTIVES: To evaluate the effects of once-daily opicapone on levodopa plasma pharmacokinetics and motor response when added to two different levodopa dosing regimens. METHODS: A total of 24 patients with PD and motor fluctuations were enrolled in an exploratory, open-label, modified cross-over trial...
November 2022: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
118635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.